Recommend Human Vaccines to your librarian for 2008. Download form here.
Email this page
Print this page
Commentary
Protective immunity following vaccination: How is it defined?
Ian J. Amanna, Ilhem Messaoudi and Mark K. Slifka
volume 4 | issue 4
july/august 2008Pages: 316 - 319
Subscribe to this journal for $79/year
Vaccination represents an important medical breakthrough pioneered by Edward Jenner over 200 years ago when he developed the world’s first vaccine against smallpox. To this day, vaccination remains the most effective means available for combating infectious disease. There are currently over 20 vaccines licensed for use within the US with many more vaccines in the R&D pipeline. Although vaccines must demonstrate clinical efficacy in order to receive FDA approval, the correlates of immunity vary remarkably between different vaccines and may be based primarily on animal studies, clinical evidence, or a combination of these sources of information. Correlates of protection are critical for measuring vaccine efficacy but researchers should know the history and limitations of these values. As vaccine technologies advance, the way in which we measure and define protective correlates may need to evolve as well. Here, we describe the correlates of protective immunity for vaccines against smallpox, tetanus, yellow fever, and measles and compare these to a more recently introduced vaccine against varicella zoster virus, wherein a strict correlate of immunity has yet to be fully defined.
Authors
Ian J. Amanna
Vaccine and Gene Therapy Institute; Oregon Health & Science University; Beaverton, Oregon USA
Ilhem Messaoudi
Vaccine and Gene Therapy Institute; Oregon Health & Science University; Beaverton, Oregon USA
Mark K. Slifka
Vaccine and Gene Therapy Institute; Oregon Health & Science University; Beaverton, Oregon USA